642 related articles for article (PubMed ID: 17956909)
1. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
3. Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study.
Kish SJ; Fitzmaurice PS; Chang LJ; Furukawa Y; Tong J
J Psychopharmacol; 2010 Feb; 24(2):281-4. PubMed ID: 18832433
[TBL] [Abstract][Full Text] [Related]
4. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Piccini P; Weeks RA; Brooks DJ
Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
[TBL] [Abstract][Full Text] [Related]
5. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography of striatal serotonin transporters in Parkinson disease.
Kerenyi L; Ricaurte GA; Schretlen DJ; McCann U; Varga J; Mathews WB; Ravert HT; Dannals RF; Hilton J; Wong DF; Szabo Z
Arch Neurol; 2003 Sep; 60(9):1223-9. PubMed ID: 12975287
[TBL] [Abstract][Full Text] [Related]
7. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures.
Carvey PM; Ptak LR; Nath ST; Sierens DK; Mufson EJ; Goetz CG; Klawans HL
Exp Neurol; 1993 Mar; 120(1):149-52. PubMed ID: 8097475
[TBL] [Abstract][Full Text] [Related]
8. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
Kaufman MJ; Madras BK
Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
[TBL] [Abstract][Full Text] [Related]
9. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
[TBL] [Abstract][Full Text] [Related]
10. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
11. High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain.
Rothman RB; Jayanthi S; Wang X; Dersch CM; Cadet JL; Prisinzano T; Rice KC; Baumann MH
Synapse; 2003 Dec; 50(3):233-9. PubMed ID: 14515341
[TBL] [Abstract][Full Text] [Related]
12. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
14. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
[TBL] [Abstract][Full Text] [Related]
15. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum.
Kish SJ; Shannak K; Hornykiewicz O
Ann Neurol; 1987 Sep; 22(3):386-9. PubMed ID: 2445259
[TBL] [Abstract][Full Text] [Related]
16. Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.
Tong J; Hornykiewicz O; Kish SJ
Arch Neurol; 2006 Dec; 63(12):1724-8. PubMed ID: 17172611
[TBL] [Abstract][Full Text] [Related]
17. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.
Zeng BY; Iravani MM; Jackson MJ; Rose S; Parent A; Jenner P
Neurobiol Dis; 2010 Dec; 40(3):599-607. PubMed ID: 20713157
[TBL] [Abstract][Full Text] [Related]
18. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression.
Mathews TA; Fedele DE; Coppelli FM; Avila AM; Murphy DL; Andrews AM
J Neurosci Methods; 2004 Dec; 140(1-2):169-81. PubMed ID: 15589347
[TBL] [Abstract][Full Text] [Related]
19. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.
Kish SJ; Shannak K; Hornykiewicz O
N Engl J Med; 1988 Apr; 318(14):876-80. PubMed ID: 3352672
[TBL] [Abstract][Full Text] [Related]
20. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease.
Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
Mov Disord; 2010; 25 Suppl 1():S174-9. PubMed ID: 20187238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
